NEW YORK, Feb. 13, 2019 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq:YMAB) a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer announced today that its Chief Scientific Officer, Mahiuddin Ahmed, PhD, will give a presentation titled “Past, Present and Future of Omburtamab for the Treatment of B7H3(+) tumors” at PEGS Boston on April 8, 2019 at 11:20 am EDT.
About Y-mAbs:
Y-mAbs is a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. The Company has a broad and advanced product pipeline, including two pivotal-stage product candidates—naxitamab and omburtamab—which target tumors that express GD2 and B7-H3, respectively.